On January 3, 2022, AffaMed Therapeutics and Hanmi Pharmaceutical Co., Ltd., announced that they had reached a licensing agreement to promote the development, production and commercialization of Risuteganib (Luminate), the first intravitreal injection product of Integrin regulator in Greater China (including mainland China, Hong Kong, Macao and Taiwan).
AffaMed Therapeutics is a late clinical-stage biopharmaceutical company focused on the development and commercialization of transformative pharmaceutical products, digital therapies and medical device products that address critical unmet medical needs in ophthalmology, neurology and psychiatric disorders for patients in Greater China and around the world. Hanmi Pharmaceutical Co., Ltd., is a Korean-based pharmaceutical company with outstanding integrated R&D capabilities in biopharmaceuticals, New Chemical Entities (NCE) and fixed-dose combination projects.
JunHe was entrustment of AffaMed Therapeutics and was responsible for the modification and negotiation of the license agreement and other relevant ancillary agreements. Throughout the entire transaction process, JunHe provided high-quality, rigorous and efficient professional legal services, which was highly praised by the clients.
This project was led by Dr. WANG, Zhaohui (Zoe). It was managed by Partner Mr. ZHAO, Hao (Gerry) and Partner Ms. LIANG, Chunjuan (Virginia).